Fundraising Fox
/Companies
Sign in

Plasmatech Biopharmaceuticals

NASDAQ: ABEO

Dallas, US · Delaware corporation

Find your way into Plasmatech Biopharmaceuticals

Sign up to see every warm intro you have to Plasmatech Biopharmaceuticals

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Plasmatech Biopharmaceuticals team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Abeona Therapeutics develops and commercializes cell and gene therapies for rare genetic diseases, including ZEVASKYN, an FDA-approved autologous gene-modified cell therapy for wounds in recessive dystrophic epidermolysis bullosa, along with a portfolio of adeno-associated virus-based gene therapies for ophthalmic disorders.

Biotech

Founders & leadership

JH
Jeffrey H. DavisExecutive
SB
Stephen B. ThompsonExecutive
BO
Brendan O'MalleyChief Legal Officer
JV
Joseph VazzanoChief Financial Officer
MV
Madhav VasanthavadaChief Commercial Officer

Board

SH
Steven H. RouhandehBoard director
MA
mark AlvinoBoard director
TW
Todd WidderBoard director
MJ
Mark J. AhnBoard director
SB
Stephen B. HowellBoard director

Reported raises · per SEC filings

Form D private placements

$23.7M disclosed across 2 of 4 rounds · 1900–2015

▶$13.7MraisedJun 2015 · 17 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen B. HowellDirector
  • Jeffrey H. DavisDirector
  • Tim MillerExecutive Officer, Director
  • Steven H. RouhandehExecutive Officer
  • Stephen B. ThompsonExecutive Officer
  • Todd WiderDirector
  • Mark J. AhnDirector
  • Mark AlvinoDirector
Offering amount
$22.7M
Amount sold
$13.7M
First sale
May 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedMay 2015 · 2 investors · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • Jeffrey H. DavisDirector
  • Steven H. RouhandehExecutive Officer
  • mark AlvinoDirector
  • Mark J. AhnDirector
  • Stephen B. ThompsonExecutive Officer
  • Todd WidderDirector
  • Stephen B. HowellDirector
Offering amount
$10M
Amount sold
$10M
Sales commissions
$1.1M
Placement agents
H. C. Wainwright & Co., LLC
First sale
May 2015
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Plasmatech Biopharmaceuticals do?
Abeona Therapeutics develops and commercializes cell and gene therapies for rare genetic diseases, including ZEVASKYN, an FDA-approved autologous gene-modified cell therapy for wounds in recessive dystrophic epidermolysis bullosa, along with a portfolio of adeno-associated virus-based gene therapies for ophthalmic disorders.
How much funding has Plasmatech Biopharmaceuticals raised?
Plasmatech Biopharmaceuticals has disclosed $23.7M raised across 2 of its 4 known rounds.
Where is Plasmatech Biopharmaceuticals headquartered?
Plasmatech Biopharmaceuticals is headquartered in Dallas, US.